PMID- 37841752
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 1758-8340 (Print)
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Linking)
VI  - 15
DP  - 2023
TI  - CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with 
      specific regard to cardiotoxicity - a narrative review.
PG  - 17588359231205848
LID - 10.1177/17588359231205848 [doi]
LID - 17588359231205848
AB  - Breast cancer is characterized by the uncontrolled proliferation of breast cells, 
      with a high incidence reported in 2020 to have affected over 2 million women. In 
      recent years, the conventional methods of treating breast cancer have involved 
      radiotherapy and chemotherapy. However, the emergence of CDK4/6 inhibitors has 
      shown potential as a promising cancer therapy. Cyclin-dependent kinases (CDK) 
      inhibitors are a class of molecules that impede the formation of an active kinase 
      complex, thereby hindering its activity and consequently halting the progression 
      of the cell cycle. It was discovered that they have a significant impact on 
      impeding the progression of the cancer. This is evident with the Food and Drug 
      Administration's approval of drugs such as palbociclib, ribociclib, and 
      abemaciclib for hormone receptor-positive metastatic breast cancer in combination 
      with specific endocrine therapies. In spite of enormous success in breast cancer 
      treatment, certain obstacles have emerged, such as therapy resistance, side 
      effects, and most of all, cardiotoxicity. Some of these drawbacks have been 
      successfully overcome by dosage reduction, different combinations of the drugs, 
      and the assessment of each patient's condition and suitability prior to 
      treatment. Yet other drawbacks still require tenacious research, especially 
      certain cases of cardiotoxicities. This article delves into the biological 
      mechanisms of CDK4/6 in the cell cycle and cancer, as well as the clinical 
      advantages and most common adverse events (AEs) associated with CDK4/6 
      inhibitors. The primary objective of this review is to provide a comprehensive 
      analysis of cardiotoxic AEs and elucidate the underlying pathophysiological 
      mechanisms responsible for the cardiotoxicity of CDK4/6 inhibitors.
CI  - (c) The Author(s), 2023.
FAU - Pavlovic, Dragica
AU  - Pavlovic D
AUID- ORCID: 0000-0002-7474-7495
AD  - Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, 69 
      Svetozar Markovic Street, Kragujevac 34000, Serbia.
FAU - Niciforovic, Danijela
AU  - Niciforovic D
AUID- ORCID: 0009-0001-6123-456X
AD  - Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, 
      Serbia.
FAU - Papic, Dragana
AU  - Papic D
AD  - Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, 
      Kragujevac, Serbia.
FAU - Milojevic, Katarina
AU  - Milojevic K
AUID- ORCID: 0009-0000-3056-1608
AD  - Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, 
      Serbia.
FAU - Markovic, Marina
AU  - Markovic M
AD  - Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, 
      Serbia.
AD  - Department of Internal Medicine, Faculty of Medical Sciences, University of 
      Kragujevac, Kragujevac, Serbia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231011
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC10571689
OTO - NOTNLM
OT  - CDK4/6 inhibitors
OT  - adverse events
OT  - breast cancer
OT  - cardiotoxicity
OT  - therapy
COIS- The authors declare that there is no conflict of interest.
EDAT- 2023/10/16 06:48
MHDA- 2023/10/16 06:49
PMCR- 2023/10/11
CRDT- 2023/10/16 04:40
PHST- 2023/06/04 00:00 [received]
PHST- 2023/09/18 00:00 [accepted]
PHST- 2023/10/16 06:49 [medline]
PHST- 2023/10/16 06:48 [pubmed]
PHST- 2023/10/16 04:40 [entrez]
PHST- 2023/10/11 00:00 [pmc-release]
AID - 10.1177_17588359231205848 [pii]
AID - 10.1177/17588359231205848 [doi]
PST - epublish
SO  - Ther Adv Med Oncol. 2023 Oct 11;15:17588359231205848. doi: 
      10.1177/17588359231205848. eCollection 2023.